A19215
SARS-CoV-2 neutralizing antibody
Size
£575.00
- SKU:
- A19215
- Molecular Weight:
- Refer to figures
- Species Reactivity:
- Virus
- Purity:
- >95%
- Storage Conditions:
- -20[o]C/-70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- Recombinant protein (or fragment).This information is considered to be commercially sensitive.
- Formulation:
- SARS-COV-2 Neutralizing Antibody is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 0.496 ug/mL using SARS-CoV-2 Inhibitor Screening Kit (Cat. No. RK04149).
- Extra Details:
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection caused COVID-19. This response focuses on the mechanism by which SARS-CoV-2 enters host cells, specifically the binding of the spike(S) protein to its receptor angiotensin-converting enzyme 2 (ACE2) and subsequent membrane fusion. SARS-CoV-2 neutralizing antibodies have been developed for preventive or therapeutic uses. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein1-5 show promise therapeutically .Neutralizing antibodies can block infection, clear pathogens, and are essential to provide long-term immunity. While neutralizing antibodies target the spike protein, their neutralization potency and breadth vary according to recognition epitopes.
- Shipping Conditions:
- Dry Ice